Immunosyn Corporation (fka IMYN)

[ScorpGirl]

Thanks for the link, I will check it out when I'm not at the office. I haven't been on the board for awhile -- been too busy chasing my pennies from the holes in my pockets!! What's going on with this stock anyhow??? I guess we will all have to be more patient due to the economics disaster.

[PMS Girl]

Osmond goes to Hollywood

http://tvwatch.people.com/2009/01/29/wednesdays-idol%20-an-osmond-goes-to-hollywood/

[Tina]

Hi SG, I believe MS progresses in various stages in deteriorating the immune system and destroying nerve cells. I'll have to do some more research on him but he may be in the early stages of the disease. He could also be in remission and not be having flare ups.

It's a very sad and debilitating disease. I've seen a good friend years ago suffer from it but she wasn't as fortunate to have the kind of medicine that's available today.

[ScorpGirl]

Yes, it is sad that he has MS too. Honestly, you could not tell a thing by seeing him. If it weren't for the video they showed on him, it would have been completely transparent to the audience. I still have all good hope for this drug and the future of the company. The people I know who are close to the company continue to be very passionate about its future and projected success.

Take care,
SG

[Tina]

Hi SG! Been a while! So good to see you again.

I missed that episode :(

Thanks for telling us about it. That's sad that one of his sons has it as well. You're right, it would have been a huge boost if they had spoken about the drug as well for the son.

Hope you have a good weekend

[ScorpGirl]

Hey TM ~

Did you see (or anyone else out there) see American Idol on Tuesday night 1/27 when the judges held auditions in in Salt Lake City? The first audition was Alan Osmond's 20-something year-old son. He did okay but could have chosen a better song to sing. Anyhow, while I believe it was pretty much already decided he was a shoe-in, I found it interesting that he also has MS. They talked a bit about the fact that he used to be confined to a wheelchair and had trouble getting his fingers to work when he tried to play his guitar. His audition had him walking fine (no guitar with him, but fingers appeared to be working well) and functioning normally. His family, including Mom and Dad were there with him and his Dad, Alan looked great. I would be of the assumption that his son is benefiting from the same wonderful effects of the drug his father takes for his illness. There must be some sort of decision that has been made for his son not to be involved as an advocate.......... too bad, it would give that much more substance to the benefits SF1019 offers.

Hope everyone is well amongst this economic shakeup.

ScorpGirl

[PMS Girl]

There is no love out there anymore!

[Tina]

IMYN = HOT HOT HOT today!

[Tina]

Nov. 16, 2008
Several emails asking what I am doing to improve my health.
Besides Immunosyn, I have been only eating organic and natural foods, drinking lots of water, getting more sleep by going to bed early and getting up earlier. Less Meat, WALKING, I found that Essential oils are great! Went to a Hormone doctor and am taking natural vitamins and cremes to get balanced. Feeling good!

A truth that I learned: Faith is more than a feeling. Faith is a decision! Decide to get better!

Also: "Trust in the Lord with ALL thine heart and lean NOT unto thine own understanding. In ALL thy ways, acknwledge HIM, and HE shall direct thy path!" Proverbs 3: 6

[Tina]

IMYN News (wow the promoter on this one is slacking lol)

LA JOLLA, Calif., Nov 18, 2008 (BUSINESS WIRE) -- Immunosyn Corporation
(OTCBB:IMYN), a biotechnology firm that has obtained exclusive worldwide
marketing, sales and distribution rights to the biopharmaceutical SF-1019 from
its affiliate Argyll Biotechnologies, LLC, has announced its results for the
quarter ending September 30, 2008.

For the quarter ended September 30, 2008, the company incurred $141,051.00 in
general and administrative expenses and $16,034.00 in interest expense. As a
result, the company had a Net Loss of $157,085.00 for the third quarter of 2008.
During the same period in 2007, the company incurred $112,850.00 in general and
administrative expenses, interest expense of $6,731.00 and had a Net Loss of
$119,581.00. Net loss year to date of $991,291.00 has been funded from advances
by affiliates of $217,466.00, accounts payable of $125,008.00, accrued expenses
of ($6,600.00) and services rendered for stock of $592,457.00. Immunosyn has had
no revenue to date as Argyll Biotechnologies, LLC is still in the process of
obtaining governmental and regulatory approval for SF-1019.

"We have continued to significantly control costs this quarter and appreciated
the advances from affiliates," noted Stephen D. Ferrone, Immunos yn's CEO. "In
2008, Argyll Biotechnologies, LLC has reported positive research results for
SF-1019 and Immunosyn hopes to add shareholder value by striving for financial
efficiency in the execution of its marketing and distribution strategy when
approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC," added
Ferrone.

"On that note, Argyll Biotech has reported to Immunosyn that a Physician
Sponsored IND Application to the Food and Drug Administration in the U.S. for a
Phase II Clinical Trial for Multiple Sclerosis utilizing SF-1019 has been
submitted. If the submitting doctor is successful in gaining approval for his
Clinical Trial, Argyll Biotech intends to supply SF-1019 at no cost to the
physician for use in the trial. The FDA response timeline guidance would suggest
that it would take approximately three to six months from the date of submission
until approval and commencement of a trial for MS," he concluded.

Research suggests that SF-1019 has analgesic properties with a perceived ability
to substantially reduce the inflammation present in a number of clinical
conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating
Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), and
other auto-immune and neurological disorders. A limited proof of concept trial
for SF-1019 in Europe has shown positive results in effectively treating
diabetic ulcers. Immunosyn went public in January 2007 and its stock began
trading on October 26, 2007 on the OTCBB under the symbol "IMYN."

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTCBB:IMYN) plans to market
and distribute life enhancing therapeutics. Currently, the company has exclusive
worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to
market, sell and distribute SF-1019, a compound that was developed from
extensive research into Biological Response Modifiers (BRMs). Argyl l Biotech is
responsible for all costs relating to the clinical testing/trials in the U.S.
with the FDA, EMEA / MHRA in Europe and other jurisdictions Argyll Biotech deems
appropriate. Argyll Biotech is also responsible for all research and product
development, regulatory approvals, production and product support. Argyll
Biotechnologies, LLC has initiated the process for regulatory approval of
SF-1019 in several countries and preparations for clinical trials are underway
in both the US and Europe. Research suggests that SF-1019 has the potential to
affect a number of clinical conditions including complications from Diabetic
Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune
disorders such as Multiple Sclerosis (MS) and neurological disorders such as
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic
Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are
based on assumptions that management believes are reasonable based on currently
available information, and include statements regarding the intent, belief or
current expectations of the Company and its management. Prospective investors
are cautioned that any such forward-looking statements are not guarantees of
future performance, and are subject to a wide range of business risks, external
factors and uncertainties. Actual results may differ materially from those
indicated by such forward-looking statements. For additional information, please
consult the Company's most recent public filings and Annual Report on Form
10-KSB for its most recent fiscal year. The Company assumes no obligation to
update the information contained in this press release, whether as a result of
new information, future events or otherwise.

SOURCE: Immunosyn Corporation



CONTACT:
The Blaine Group
Lisa Baker/Devon Blaine
310-360-1499
310-360-1498 (FAX)
[e-mail]

[PMS Girl]

I see believers out there today.

The stock has life still...up $.40

[PMS Girl]

I firmly believe good news will be out soon.

Give it a couple of days...now would be a good time to firm up those positions.

[PMS Girl]

I know, I know....

The company should have news out soon....

[cbfromli]

no..just the good old PMS

[Tina]

No news since August

any updated PMS?

[PMS Girl]

Where is the love out there?

Supporters have fallen....

[PMS Girl]

I guess we still have believers out there...

Traded at $1 sooner than I thought!

[Tina]

share structure missing out of ibox for some reason

Outstanding Shares
272,012,347 as of May 12, 2008

may need to be updated for current

[Tina]

Immunosyn Corp. $ 0.95

Short Interest (Shares Short) 27,900

[Tina]

IMYN pincher action

[Tina]

Looks like IMYN is recovering nicely from it's lows

[PMS Girl]

Stock will continue to go up...

I believe significant things are going on! Should be close to or over $1 in a couple of weeks. IMO

[PriceIsRight]

The truth about IMYN and its principals /partners.. Thinking about investing in this one? Someone has done a lot of research:

immunosyn.wordpress.com

[Reality1]

Ruh roh!!

[PriceIsRight]

Does anyone know anything about Argyll Biotechnologies, who is the largest shareholder of IMYN and according to their website the holder of the rights to SF-1019? Have they launched any other meds or products? Has anyone checked out the principals? I would like to know more before I jump in although true to my nickname I think the price is right.

[PMS Girl]

Immunosyn Corporation Files 10-Q
Thursday August 14, 11:23 am ET

LA JOLLA, Calif.--(BUSINESS WIRE)--Immunosyn Corporation (OTCBB: IMYN - News), a biotechnology firm that has obtained exclusive worldwide marketing, sales and distribution rights to the biopharmaceutical SF-1019 from its affiliate Argyll Biotechnologies, LLC, has announced its results for the quarter ending June 30, 2008.

For the quarter ended June 30, 2008, the company incurred $629,884.00 in general and administrative expenses and $15,297.00 in interest expense which was funded from advances by affiliates of $26,527.00, accounts payable of $60,376.00, accrued expenses of ($1,498.00) and services rendered for stock of $529,250. As a result, the company had a Net Loss of $645,181.00 for the second quarter of 2008. During the same period in 2007, the company incurred $71,025.00 in general and administrative expenses, interest expense of $4,810.00 and had a Net Loss of $75,835.00. Immunosyn has had no revenue to date as Argyll Biotechnologies, LLC is still in the process of obtaining governmental and regulatory approval for SF-1019.

“We have continued to significantly control costs this quarter and appreciated the advances from affiliates,” noted Stephen Ferrone, Immunosyn’s CEO. “In 2008, Argyll Biotechnologies, LLC has reported positive research results for SF-1019 and Immunosyn hopes to add shareholder value by striving for financial efficiency in the execution of its marketing and distribution strategy when approvals for SF-1019 are obtained by Argyll Biotechnologies, LLC,” added Ferrone.

Research suggests that SF-1019 has analgesic properties with a perceived ability to substantially reduce the inflammation present in a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders. A limited proof of concept trial for SF-1019 in Europe has shown positive results in effectively treating diabetic ulcers. Immunosyn went public in January 2007 and its stock began trading on October 26, 2007 on the OTCBB under the symbol “IMYN.”

About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (OTCBB: IMYN - News) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS).

The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company’s most recent public filings and Annual Report on Form 10-KSB for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.

Contact:
The Blaine Group
Lisa Baker/Devon Blaine
310-360-1499
310-360-1498 (FAX)
[e-mail]

[Tina]

green so far :)

[midtownmurphy]

Looks like where getting active today.)))))))))))

[Tina]

Good morning mm

News was definitely nice. I'v been radaring it closely.

BIOS definitely rock!

[midtownmurphy]

T love the news, and bio-techs. I'm keeping my remaining 150k shares until it hits $5.00 again.

[Tina]

LA JOLLA, Calif., Aug 12, 2008 (BUSINESS WIRE) -- Immunosyn Corporation
(OTCBB:IMYN) announced today that marketing, distribution and patient treatment
approval has been granted by the Ministry of Health Malaysia for SF-1019 in the
Private Pay Heath Sector in Malaysia. The marketing name for SF-1019 in Malaysia
will be R-1818.

Argyll Biotechnologies, LLC, the licensor of SF-1019, Immunosyn's strategic
partner and its largest shareholder, has notified Immunosyn that the Ministry of
Health Malaysia has approved the importation, marketing and distribution of
SF-1019 in the Private Pay Health Sector throughout Malaysia for the treatment
of Diabetic Mellitus, Diabetic Neuropathy, Diabetic Ulcers as well as other
Chronic Inflammatory and Degenerative Diseases. The Ministry of Health has also
given approval for treating physicians in Malaysia to prescribe and export
SF-1019 to patients residing outside of Malaysia.

"Today marks an important chapter in our company's entrance into the global
markets and we are looking forward to commercially launching SF-1019," said
Stephen D. Ferrone, President and CEO of Immunosyn.

"Malays ia is the first country to grant regulatory marketing, treatment and
distribution approval of SF-1019," Ferrone added, "Immunosyn hopes to make
Malaysia a central distribution hub in order for patients worldwide to be able
to receive the benefit of SF-1019."

Argyll Biotech has worked for several years on developing the manufacturing
processes, protocols, safety procedures and guidelines for SF-1019. Immunosyn,
together with Argyll Biotech, is working to finalize Distribution Management and
Information Component Systems that will be implemented to define protocols to
assure patient safety and regulatory compliance in Malaysia as well as
throughout the world prior to treatment commencing. In addition, Argyll Biotech
will apply for an import license from Malaysian authorities. These steps are
expected to be completed during the fourth quarter of 2008. Argyll Biotech has
advised Immunosyn that they plan to continue the process to obtain full
regulatory approvals for the marketing of SF-1019 throughout Asia as well as in
Europe and then the U.S.

"The healthcare spending of Malaysians is incredibly high, reflecting the trend
of Malaysians towards a healthy lifestyle," stated Douglas A. McClain, Jr.,
Chairman of the Board and CFO of Immunosyn. "This is an exciting early-stage
development as this puts revenue producing capabilities within short-term range
for the company."

SF-1019 is a compound that was developed from extensive research into Biological
Response Modifiers. This research suggests that SF-1019 has the potential to
affect a number of clinical conditions including complications from Diabetes
Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune
disorders such as Multiple Sclerosis (MS) and neurological disorders. Results
from a recent study undertaken in Europe to evaluate the safety and efficacy of
SF-1019 in the treatment of Diabetic Ulceration and its effect on Diabetic
Polyneuropathy in Type 1 Diabetes Mellitus suggest that SF-1019 promotes wound
healing and induces growth factors.

Globally, according to Diabetes Atlas, third edition (C) International Diabetes
Federation, 2006 and www.diabetes.niddk.nih.gov:

-- Approximately 246 million people have Diabetes Mellitus

-- Estimated 50% (143 million) have Diabetic Neuropathy (DN)

-- 1 in 6 (41 million) will develop a foot ulcer

Malaysia has a population of just over 25,000,000 people. According to the
Ministry of Health Malaysia, in 2008 nearly 17% of the general population of
Malaysia had Diabetes Mellitus. The Ministry states in its "Clinical Practices
Guideline for Management of Diabetic Foot" that, "Diabetic foot complications
pose a substantial problem in the Malaysian diabetic population. They are a
major source of morbidity, a leading cause of hospital bed occupancy and account
for substantial health care costs and resources."

In a report released in August, 2004, the Ministry noted, "The prevalence of
foot ulceration in patients attending a diabetic outpatient clinic in Malaysia
has been reported as 6%. Foot complications have been found to account for 12%
of all diabetic hospital admissions which in turn made up 17% of all hospital
admissions at Hospital Kuala Lumpur, Malaysia."

In addition to its own residents, Malaysia has a Health Tourism Industry which
according to the Association of Private Hospitals Malaysia has an annual growth
rate of 25 - 30% per year. The association attributes this growth rate to many
factors including, but not limited to, the choice of world class infrastructure
facilities, combined with high qualified, experienced practitioners and
competitive, affordable pricing.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (OTCBB:IMYN) plans to market
and distribute life enhancing therapeutics. Currently, the company has exclusive
worldwide rights from its largest shareholder , Argyll Biotechnologies, LLC, to
market, sell and distribute SF-1019. Argyll Biotechnologies, LLC has initiated
the process for regulatory approval of SF-1019 in several countries and
preparations for clinical trials are underway in both the US and Europe. (For
more information on Immunosyn and SF-1019 go to www.immunosyn.com).

The above news release contains forward-looking statements. These statements are
based on assumptions that management believes are reasonable based on currently
available information, and include statements regarding the intent, belief or
current expectations of the Company and its management. Prospective investors
are cautioned that any such forward-looking statements are not guarantees of
future performance, and are subject to a wide range of business risks, external
factors and uncertainties. Actual results may differ materially from those
indicated by such forward-looking statements. For additional information, please
consult the Company's most recent public filings and Annual Report on Form
10-KSB for its most recent fiscal year. The Company assumes no obligation to
update the information contained in this press release, whether as a result of
new information, future events or otherwise.

SOURCE: Immunosyn Corporation



CONTACT: The Blaine GroupLisa Baker/Devon Blaine, 310-360-1499310-360-1498 (FAX)[e-mail]

[PMS Girl]

Happy Friday!

Nice open again. Like to see supporters out there!

[PMS Girl]

Nice open again today!

[PMS Girl]

It's worth calling in your order.

I know it's time consuming but it's worth it.

[PMS Girl]

Looking good today!

There is life out there :)

[PMS Girl]

And who is going to take the time to do that?

I know its a paid however calling in limit orders will probably help.

[Tina]

not if others aren't calling it in

need to fix the restricted buying before this stock can move north

[PMS Girl]

It's worth calling to place an order

at these levels.

[Tina]

Not sure but think the company would have to do that

Just tried placing a buy with all three - Atrade/Scottrade/Etrade and no can do on line


Please contact your local branch about placing an order on this security.

Not being able to place an order would definitely hinder people form purchasing the stock

[youhavenoidea]

Immunosyn Corp (BB) (IMYN)$1.55Change:-0.05 (-3.13%)Volume:3259:40:21 EDTJul-29-08


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=30823415

[PMS Girl]

Can anyone find out why?

[Tina]

I think it would be a lot higher lizzy but for some reason it's been restricted

[PMS Girl]

My point that I was making is that they can project revenues.

[fastlizzy]

Did you ever see this....it came out on the 16th.....

maybe that's why the uptick that day.....

[PMS Girl]

Company Profile

http://publish.marketupdatenetwork.com/publish/180

[youhavenoidea]

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=29412964

[PMS Girl]

IMYN turns into a Revenue Generating Bio-Tech Company

Versus Bio-Tech Developmental Company. (Think About It)

Significant things will happen now that the product is available in the U.S.

[PMS Girl]

Take Position Now!

Great prices..you know the stock will climb. Spread the word: The drug is available in the USA. :)

[bird_splitter]

Let's shake your money maker!!

GO IMYN to da moon!!

[Tina]

Good wonderful Sunday mm!

As long as we keep making that CA CHING, that's what counts!

IMYN was definitely a sweet stock and I wouldn't doubt one bit that it's not still going to be a big future money maker!